Anti-TNF Therapy
- Authors: Irina Udalova1, Claudia Monaco2, Jagdeep Nanchahal3, Marc Feldmann4
- Editor: Siamon Gordon5
-
VIEW AFFILIATIONS HIDE AFFILIATIONSAffiliations: 1: Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Botnar Research Centre, Headington, Oxford OX3 7LD, United Kingdom; 2: Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Botnar Research Centre, Headington, Oxford OX3 7LD, United Kingdom; 3: Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Botnar Research Centre, Headington, Oxford OX3 7LD, United Kingdom; 4: Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Botnar Research Centre, Headington, Oxford OX3 7LD, United Kingdom; 5: Oxford University, Oxford, United Kingdom
-
Received 09 September 2015 Accepted 26 October 2015 Published 12 August 2016
- Correspondence: Marc Feldmann, [email protected]

-
Abstract:
Tumor necrosis factor (TNF) is one of the most important cytokines produced by macrophages. TNF is a very important component of host defense, released very rapidly after all types of injuries and stimuli. The kinetics of TNF release are short, and so it is perhaps not surprising that prolonged TNF production is associated with pathology. This was first elucidated in rheumatoid arthritis but extends to other chronic inflammatory diseases such as Crohn’s disease and psoriasis. In this chapter, the discovery of anti-TNF therapy is reviewed, with its benefit but also its limitations. The potential of anti-TNF therapy in other diseases, e.g., cardiovascular and fibrosis, is discussed, as is the opportunity to define ways of blocking TNF synthesis.
-
Citation: Udalova I, Monaco C, Nanchahal J, Feldmann M. 2016. Anti-TNF Therapy. Microbiol Spectrum 4(4):MCHD-0022-2015. doi:10.1128/microbiolspec.MCHD-0022-2015.




Anti-TNF Therapy, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/microbiolspec/4/4/MCHD-0022-2015-1.gif /docserver/preview/fulltext/microbiolspec/4/4/MCHD-0022-2015-2.gif

References

Article metrics loading...
Abstract:
Tumor necrosis factor (TNF) is one of the most important cytokines produced by macrophages. TNF is a very important component of host defense, released very rapidly after all types of injuries and stimuli. The kinetics of TNF release are short, and so it is perhaps not surprising that prolonged TNF production is associated with pathology. This was first elucidated in rheumatoid arthritis but extends to other chronic inflammatory diseases such as Crohn’s disease and psoriasis. In this chapter, the discovery of anti-TNF therapy is reviewed, with its benefit but also its limitations. The potential of anti-TNF therapy in other diseases, e.g., cardiovascular and fibrosis, is discussed, as is the opportunity to define ways of blocking TNF synthesis.

Full text loading...
Supplemental Material
No supplementary material available for this content.